Q2 EPS Estimates for HeartSciences Raised by Maxim Group

HeartSciences Inc. (NASDAQ:HSCS) – Stock analysts at Maxim Group boosted their Q2 2027 earnings estimates for HeartSciences in a research note issued to investors on Thursday, September 17th. Maxim Group analyst A. Klee now expects that the company will earn ($0.72) per share for the quarter, up from their prior estimate of ($0.75). The consensus estimate for HeartSciences’ current full-year earnings is ($2.99) per share. Maxim Group also issued estimates for HeartSciences’ Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.64) EPS, FY2027 earnings at ($2.88) EPS, Q1 2028 earnings at ($0.65) EPS, Q2 2028 earnings at ($0.61) EPS, Q3 2028 earnings at ($0.46) EPS, Q4 2028 earnings at ($0.32) EPS and FY2028 earnings at ($2.01) EPS.

Other research analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. Wall Street Zen upgraded HeartSciences from a “sell” rating to a “hold” rating in a research report on Sunday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

HeartSciences Trading Down 1.5%

HeartSciences stock opened at $4.61 on Monday. HeartSciences has a 1-year low of $1.63 and a 1-year high of $5.25. The firm has a market capitalization of $22.13 million, a PE ratio of -1.43 and a beta of 1.85. The firm’s 50 day simple moving average is $2.89 and its 200 day simple moving average is $2.46.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.10 million.

About HeartSciences

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.